Nov 18 (Reuters) – Bristol Myers Squibb said on Wednesday that preliminary data from two late-stage studies showed its experimental treatment for psychosis associated with Alzheimer’s disease improved patient symptoms.
Investors are closely watching whether Cobenfy, currently approved in the United States to treat schizophrenia, can be expanded into Alzheimer’s treatment and drive future growth for the company.
Here are more details:
• In both studies, Cobenfy — chemically known as KarXT — was associated with improvements in clinician-observed scores of hallucinations and delusions and overall disease severity, Bristol said
• Alzheimer’s is a devastating neurodegenerative disease and the most common type of dementia in adults. The company estimates about 30-50% of Alzheimer’s patients experience symptoms such as hallucinations and delusions
• The preliminary results are the first to be disclosed from the ongoing late-stage program
• In a 12-week study, patients treated with the drug showed an average reduction in symptoms such as hallucination and delusion by 12 points from 14.4 at the start of the study
• Among patients who completed treatment for 52 weeks, the drug was generally well tolerated, with low rates of discontinuation, the drugmaker said
• At 52 weeks, treatment-related side effects occurred in 65.1% of patients, serious treatment-related side effects occurred in 7.7%, while 4.7% discontinued treatment due to side effects
(Reporting by Sneha S K; Editing by Diti Pujara)

